Fundamental Analysis Stories

<div class='circular--portrait-small' style='font-weight: 700;background:#754DEB;color: #F0FFF0;font-size:1.1em;padding-top: 10px;;'>SE</div>
  six days ago at Macroaxis 
By Gabriel Shpitalnik
SunCoke Energy Revenue Per Employee is projected to decrease significantly based on the last few years of reporting. The past year's Revenue Per Employee was at 1.37 Million. The current year Earnings Before Interest Taxes and Depreciation Amortization EBITDA is expected to grow to about 1 M, whereas Net Income Per Employee is forecasted to decline to (133.5 K). SunCoke Energy is scheduled to announce its earnings tomorrow. The upcoming quarterly report is expected on the 3rd of August 2020. While some generation-Y investors are indifferent towards basic materials space, it makes sense to go over SunCoke Energy using its fundamentals . We will look into reasons why it is still very possible for the company to generate above-average returns. SunCoke Energy barely shadows the market. We can now analyze SunCoke as a potential investment option for your portfolios.
<div class='circular--portrait-small' style='font-weight: 700;background:#FF0F00;color: #FFFFF0;font-size:1.1em;padding-top: 10px;;'>CN</div>
  six days ago at Macroaxis 
By Raphi Shpitalnik
Ceragon Networks Price to Sales Ratio is comparatively stable at the moment as compared to the past year. Ceragon Networks reported Price to Sales Ratio of 0.59 in 2019. Return on Invested Capital is likely to grow to 0.0486 in 2020, whereas Average Equity is likely to drop slightly above 146 M in 2020. There are many examples of prices decreasing after a drastic change in one of the technical and fundamental indicators. In this short article, we will review a few of Ceragon Networks' essential fundamentals. We will analyze why Ceragon Networks investors may still consider a stake in the business. Will private investors continue to hold, or should we expect a sell-off?
<div class='circular--portrait-small' style='font-weight: 700;background:#FF0000;color: #F5FFFA;font-size:1.1em;padding-top: 10px;;'>AI</div>
  six days ago at Macroaxis 
By Raphi Shpitalnik
AC Immune Earnings per Basic Share are comparatively stable at the moment as compared to the past year. AC Immune reported Earnings per Basic Share of 0.64 in 2019. Earnings per Diluted Share is likely to grow to 0.69 in 2020, whereas Market Capitalization is likely to drop slightly above 572.8 M in 2020. There are many examples of share prices decreasing after an abrupt shift in one of the primary indicators. Let's review some of AC Immune's important ratios. We will look into reasons why it is still very possible for the company to generate above-average returns. The company almost neglects market trends. We can now break down AC Immune as a potential investment option for your portfolios.
<div class='circular--portrait-small' style='font-weight: 700;background:#FF0F00;color: #FFFFF0;font-size:1.1em;padding-top: 10px;;'>CF</div>
  over a week ago at Macroaxis 
By Raphi Shpitalnik
CNA Financial Average Assets are projected to increase significantly based on the last few years of reporting. The past year's Average Assets were at 59.88 Billion. The current year Earnings Before Interest Taxes and Depreciation Amortization EBITDA is expected to grow to about 1.5 B, whereas Net Income Per Employee is forecasted to decline to about 136.6 K. One of the important factors of profitable assets selection is to know the future growth potential of an asset before buying its shares. This post will go over CNA Financial. We will evaluate if CNA Financial shares are reasonably priced going into September. Will investors continue to hold, or should we expect a sell-off?
<div class='circular--portrait-small' style='font-weight: 700;background:#006400;color: #FFE4E1;font-size:1.1em;padding-top: 10px;;'>CB</div>
  over a week ago at Macroaxis 
By Vlad Skutelnik
Catalyst Biosciences Asset Turnover is quite stable at the moment as compared to the past year. The company's current value of Asset Turnover is estimated at 0.0268. Book Value per Share is projected to rise to 5.84 this year, although the value of Earnings Before Interest Taxes and Depreciation Amortization EBITDA will most likely fall to (56.5 M). Catalyst Biosciences is scheduled to announce its earnings tomorrow. The upcoming quarterly report is expected on the 6th of August 2020. As some conservatives are trying to avoid healthcare space, we'll outline Catalyst Biosciences a little further and explain its current market possibilities. We will evaluate why we are still confident in anticipation of a recovery. Catalyst Biosciences odds of financial turmoil is under 6 percent. Will Catalyst Biosciences institutional investors continue to trade in September?
<div class='circular--portrait-small' style='font-weight: 700;background:#347AFC;color: #ffffff;font-size:0.9em;padding-top: 12px;;'>LAZ</div>
  over a week ago at Macroaxis 
By Achuva Shats
Lazard Earnings per Diluted Share are fairly stable at the moment as compared to the past year. Lazard reported Earnings per Diluted Share of 2.44 in 2019. Enterprise Value over EBIT is likely to grow to 16.18 in 2020, whereas Average Assets are likely to drop slightly above 5.1 B in 2020. If you are looking to grow your portfolio over time, you may want to break down all of the essential basic indicators of your selected equities before buying their shares. In this article, we will break down Lazard. We will evaluate if Lazard shares are reasonably priced going into August. Lazard LTD Lazard probability of distress is under 41 percent. Will Lazard investors continue to purchase in August?
<div class='circular--portrait-small' style='font-weight: 700;background:#347AFC;color: #ffffff;font-size:1.1em;padding-top: 10px;;'>L3</div>
  over a week ago at Macroaxis 
By Ellen Johnson
L3Harris Debt to Equity Ratio is fairly stable at the moment as compared to the past year. L3Harris reported Debt to Equity Ratio of 2.45 in 2019. Dividend Yield is likely to grow to 0.0193 in 2020, whereas Average Assets are likely to drop slightly above 10.3 B in 2020. In spite of fairly strong basic indicators, L3Harris is not utilizing all of its potentials. The recent stock price disturbance, may contribute to a short-term swings for the investors. Will investors continue to hold, or should we expect a sell-off?
<div class='circular--portrait-small' style='font-weight: 700;background:#000000;color: #f2f2f2;font-size:0.9em;padding-top: 12px;;'>ABB</div>
  over a week ago at Macroaxis 
By Raphi Shpitalnik
AbbVie Cash and Equivalents Turnover is fairly stable at the moment as compared to the past year. AbbVie reported Cash and Equivalents Turnover of 1.41 in 2019. Return on Investment is likely to grow to 30.15 in 2020, whereas Revenue Per Employee is likely to drop slightly above 948.3 K in 2020. AbbVie Inc is scheduled to announce its earnings today. The next earnings report is expected on the 6th of November 2020. Is healthcare space attracting new sophisticated investors, let's check if AbbVie Inc is sending any bullish signals. We will evaluate why we are still confident in anticipation of a recovery. We currently estimate AbbVie as undervalued. The real value is approaching 107.11 per share.
<div class='circular--portrait-small' style='font-weight: 700;background:#169D0B;color: #E6E6FA;font-size:1.1em;padding-top: 10px;;'>LI</div>
  over a week ago at Macroaxis 
By Raphi Shpitalnik
LyondellBasell Industries Average Assets are projected to increase significantly based on the last few years of reporting. The past year's Average Assets were at 30.4 Billion. The current year Earnings Before Interest Taxes and Depreciation Amortization EBITDA is expected to grow to about 6.3 B, whereas Invested Capital is forecasted to decline to about 33.9 B. LyondellBasell Industries is scheduled to announce its earnings today. The next earnings report is expected on the 6th of November 2020. As some conservatives are trying to avoid basic materials space, we'll go over LyondellBasell Industries NV a little further and explain its current market possibilities. We will evaluate if LyondellBasell Industries shares are reasonably priced going into August. We currently estimate LyondellBasell Industries as fairly valued. The real value is approaching 66.88 per share.
<div class='circular--portrait-small' style='font-weight: 700;background:#FF6600;color: #FFFAFA;font-size:1.1em;padding-top: 10px;;'>SO</div>
  over a week ago at Macroaxis 
By Raphi Shpitalnik
Snap On Earnings before Tax are projected to increase significantly based on the last few years of reporting. The past year's Earnings before Tax were at 711.63 Million. The current year Average Equity is expected to grow to about 2.5 B, whereas Net Income Per Employee is forecasted to decline to about 38.5 K. Despite somewhat strong basic indicators, Snap On is not utilizing all of its potentials. The latest stock price disturbance, may contribute to a short-term swings for the investors. We currently estimate Snap On as fairly valued. The real value is approaching 141.93 per share.
Macroaxis is not a registered investment advisor or broker/dealer. All investments, including stocks, funds, ETFs, or cryptocurrencies, are speculative and involve substantial risk of loss. We encourage our investors to invest carefully. Much of our information is derived directly from data published by companies or submitted to governmental agencies which we believe are reliable, but are without our independent verification. Therefore, we cannot assure you that the information is accurate or complete. We do not in any way warrant or guarantee the success of any action you take in reliance on our statements or recommendations. Also, note that past performance is not necessarily indicative of future results. All investments carry risk, and all investment decisions of an individual remain the responsibility of that individual. There is no guarantee that systems, indicators, or signals will result in profits or that they will not result in losses. All investors are advised to fully understand all risks associated with any investing they choose to do. Hypothetical or simulated performance is not indicative of future results. We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown because hypothetical or simulated performance is not necessarily indicative of future results. For more information please visit our terms and condition page